John Mohr, Pharm.D., FIDP

Dr. Mohr is a pharmacist with 20 years of experience as a clinician, researcher, teacher, scientist and medical affairs leader. He began his career in clinical practice at Memorial Hermann Hospital and held the role of Assistant Professor of Medicine at the University of Texas Medical School in Houston from 2003-2007. In addition to his clinical responsibilities in the hospital, he served as an investigator for multiple phase 3 and 4 clinical trials and conducted research focused on the pharmacokinetics and pharmacodynamics of antibiotics. Dr. Mohr began his career in the pharmaceutical industry at Cubist Pharmaceuticals where he had multiple roles to support the commercialization of Cubicin within the Medical Affairs function, serving as a field medical affairs liaison and ultimately leading the medical affairs strategy group. In addition, he supported the medical affairs integration of two companies (Adalor and Optimer) upon acquisition and led the medical affairs launch of Zerbaxa and Sivextro until Cubist was acquired by Merck for $9.5 billion. Following his tenure at Cubist Pharmaceuticals, John served as Vice President of Medical Affairs at the Medicines Company where he led the medical affairs strategy for Orbactiv and Minocin IV, and as Vice President of Medical Affairs at Tetraphase, where he managed building out the medical affairs function to support the launch of Xerava. Dr. Mohr received his B.S. in Biomedical Sciences from Texas A&M University and his Pharm.D. from the University of Houston College of Pharmacy.